206 related articles for article (PubMed ID: 17649802)
1. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
2. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
3. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
4. Stool test for colorectal cancer screening--it's time to move!
Loitsch SM; Shastri Y; Stein J
Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
[TBL] [Abstract][Full Text] [Related]
5. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
7. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
[TBL] [Abstract][Full Text] [Related]
8. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
Hardt PD; Ewald N
Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
10. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
11. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
Shastri YM; Stein JM
Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
[No Abstract] [Full Text] [Related]
12. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
[TBL] [Abstract][Full Text] [Related]
13. Improved fecal DNA test for colorectal cancer screening.
Itzkowitz SH; Jandorf L; Brand R; Rabeneck L; Schroy PC; Sontag S; Johnson D; Skoletsky J; Durkee K; Markowitz S; Shuber A
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):111-7. PubMed ID: 17161655
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
Li Y; Wang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
[TBL] [Abstract][Full Text] [Related]
15. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
17. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
18. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
19. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
20. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]